“We reiterate our Buy rating and $30 target price. All relevant disclosures and certifications appear on pages 3 – 5 of this report. Stifel does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.Investment Thesis We believe Vanda’s current valuation is an attractive entry point for investors, given its accelerating base business and relatively de-risked, late-stage pipeline that we believe is under-appreciated.”,” Stifel Nicolaus’ analyst commented.
Other research analysts also recently issued research reports about the stock. TheStreet raised shares of Vanda Pharmaceuticals from a c rating to a b- rating in a research report on Friday, October 26th. Oppenheimer set a $27.00 target price on shares of Vanda Pharmaceuticals and gave the company a buy rating in a research report on Thursday, August 2nd. Seaport Global Securities reissued a buy rating and set a $26.00 target price on shares of Vanda Pharmaceuticals in a research report on Thursday, August 2nd. Citigroup raised their target price on shares of Vanda Pharmaceuticals from $27.00 to $31.00 and gave the company a buy rating in a research report on Tuesday, October 16th. Finally, Zacks Investment Research raised shares of Vanda Pharmaceuticals from a hold rating to a buy rating and set a $26.00 target price on the stock in a research report on Friday, October 12th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $26.86.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, August 1st. The biopharmaceutical company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.14. The business had revenue of $47.40 million for the quarter, compared to the consensus estimate of $47.28 million. Vanda Pharmaceuticals had a net margin of 0.73% and a return on equity of 0.68%. The company’s revenue for the quarter was up 12.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.03 EPS. As a group, equities research analysts expect that Vanda Pharmaceuticals will post -0.02 earnings per share for the current year.
Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its holdings in shares of Vanda Pharmaceuticals by 16.3% in the 2nd quarter. BlackRock Inc. now owns 4,960,924 shares of the biopharmaceutical company’s stock valued at $94,506,000 after buying an additional 693,922 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in shares of Vanda Pharmaceuticals by 12.1% in the 2nd quarter. Macquarie Group Ltd. now owns 2,555,004 shares of the biopharmaceutical company’s stock valued at $48,673,000 after buying an additional 276,057 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Vanda Pharmaceuticals by 2.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,681,250 shares of the biopharmaceutical company’s stock valued at $32,028,000 after buying an additional 41,200 shares in the last quarter. First Manhattan Co. boosted its holdings in shares of Vanda Pharmaceuticals by 478,333.0% in the 2nd quarter. First Manhattan Co. now owns 956,866 shares of the biopharmaceutical company’s stock valued at $18,228,000 after buying an additional 956,666 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Vanda Pharmaceuticals by 15.7% in the 2nd quarter. Northern Trust Corp now owns 676,300 shares of the biopharmaceutical company’s stock valued at $12,884,000 after buying an additional 91,539 shares in the last quarter. Institutional investors and hedge funds own 93.54% of the company’s stock.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Featured Story: What is Considered a Good Return on Equity (ROE)?
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.